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ABSTRACT
Charcot-Marie-Tooth (CMT) disease is one of the most common inherited disorders of the peripheral nervous system. 
Patients diagnosed with CMT disease have axonal degeneration which results in muscle wasting, sensory loss and 
weakness. These patients have a very characteristic walking gait and shape of hands, along with other changes. 
Despite many common visible changes, no singular common genetic mutation for this disease or its cure has been 
identified. Therefore more case series for this disease needs to be identified so that future studies increase our 
knowledge about this disease. Here, we present a case series of 3 out of 4 siblings who have been diagnosed with 
CMT disease. Based on their age, these siblings show the different developmental stages of this disease. More of such 
case series need to be identified and reported so that we can identify the true genetic cause of this disease and 
develop a definitive cure for it.
C A S E  R E P O R T
INTRODUCTION
Charcot-Marie-Tooth (CMT) disease was first described 
in 1886 as a peripheral nerve disorder and since then 
it is  now believed to be one of the most common 
inherited disorders of the peripheral nervous system1. 
The prevalence of CMT varies significantly across 
different countries, from 9.7/100000 in Serbia to 
82.3/100000 in Norway2. No study has been published 
from Pakistan regarding the prevalence of CMT. The 
number of genetic mutations associated with this 
disease continues to grow beyond 1000, with over 80 
genes involved3. However, the cause of a significant 
types of CMT remains unknown. Whatever the origin of 
the disorder might be, the final common pathway is 
that of axonal degeneration or demyelination involving 
mostly the largest and longest nerves4. Secondary 
axonal degeneration may lead to disability in 
demyelinating CMT and may be primary process in 
other.
The axonal degeneration in CMT disease tends to start 
in the extremities and then spreads to the proximal 
limbs which involve muscle wasting, sensory loss and 
weakness5, 6. In the feet it is observed that there are 
high arches, hammer toes, muscle wasting and 
weakness. Ultimately there is involvement of the leg 
and then the lower third of the thigh, producing the 
typical distal atrophy of the lower limbs. At this point 
the hands and forearms are also affected, while the 
same pattern evolves to include sensory loss and 
reduction of the deep tendon reflexes. 
Disease onset is usually in the first two decades and 
then there is slow progression over decades. Usually 
the presentation includes pes cavus (or pes planus, 
often later progressing to cavus deformity); hammer 
toes; difficulty in running; twisting of the ankle and 
tripping; difficulty in walking; foot drop; steppage gait; 
wasting, weakness, and sensory loss of distal segments 
of lower and then upper limbs; difficulties in hand 
manipulation; and reduced or absent deep-tendon 
reflexes7, 8.
Currently there is no treatment available for this 
disease. Further studies are required to understand this 
rare disease and possibly develop its treatment. The 
discovery of more cases is extremely crucial to 
understand this disease and better describe its clinical 
features. In this case series we describe a family in 
which 3 out of 4 siblings have been diagnosed with 




A family presented to Aga Khan University Hospital in 
May 2018 in which 3 out of 4 siblings had difficulty 
walking in a straight line and holding objects. The 
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parents of these children were first cousins, however, 
nobody else in the family had a history of CMT or any 
other type of polyneuropathy. The symptoms of each 
patient are described below:
CASE 1:
The eldest sibling was a 13 years old male child and 
presented with difficulty in walking, foot numbness, and 
difficulty performing daily tasks, such as shirt buttoning. 
The first of these symptoms, difficulty in walking, 
started at the age of 4 years  . His birth history was 
normal, and early motor milestones were achieved on 
time. On examination there was atrophy of thenar and 
hypothenar muscles, poor hand grip, high stepping gait, 
flat feet deformity and deep tendon reflexes were 
diminished, however, sensory examination was normal 
and senses of position and vibration were intact (figure 
1A and B; Supplementary video 1). No other signs or 
symptoms were observed. EMG/NCV study was 
suggestive of sensory motor polyneuropathy.
CASE 2:
The next sibling was a 9 years old girl who presented 
with complaints of clumsiness in walking and running 
and difficulty in holding objects, which had started at 
the age of 4 years. Her birth history was normal, and 
developmental motor milestones were achieved on 
time. On examination there was high steeping gait, flat 
feet, and thin legs, wasting of muscles of hand, foot, 
and lower leg, with diminished deep tendon reflexes 
(figure 1C and D; Supplementary video 1). Sensory 
examination was normal. EMG/NCV study was 
suggestive of sensory motor polyneuropathy.
CASE 3:
The youngest sibling was a 6 years old boy who 
presented with difficulty in walking, which had started 
at the age of 5 years. His birth history was normal, and 
developmental motor milestones were achieved on 
time. On examination there was atrophy of foot and 
hand intrinsic muscles with flat feet, and thin legs, and 
diminished deep tendon reflexes (figure 1E and F; 
Supplementary video 1). Sensory examination was 
normal.
The parents were informed that there is no treatment 
available that can cure the CMT disease, however, it 
has been shown that the physical and occupational 
therapy improves the quality of life of these patients. 
The parents were also counselled about the importance 
of foot care of their children and if required, the 
possibility of getting corrective surgery. Parents were 
also informed that since this is a genetic disorder, if 
they have another child the possibility of having CMT is 
much higher in that child than average. Therefore, they 
should be very careful before making the decision of 
having another child.     
DISCUSSION:
Although CMT disease does not reduce the life 
expectancy of patients, it is an extremely debilitating 
disease. The symptoms of this disease, specially foot 
drop and a high-stepped gait can cause frequent 
tripping or falls and reduce the quality of life of patients. 
Since the definitive genetic cause of this disease is yet 
to be discovered, the treatment options remain very 
limited. Large scale drug trails with ascorbic acid have 
not shown promising results9. Drug trails in mutant 
animal model have shown effective results but these 
results were not replicated in human trails.
It is a strange fact that the common deficit found in all 
CMT disease patients is axonal degeneration involving 
mostly the largest and longest nerves10, yet the number 
of genetic mutations associated with CMT is over 
10002. Therefore, it is fair to say that the true common 
genetic cause remains unidentified. Until this genetic 
cause is identified the complete pathology of CMT 
cannot be understood and a definitive treatment 
cannot be developed. 
Here we have reported a case series of 3 siblings (from 
a family with 4 children) who have been diagnosed of 
CMT disease. The mere fact that the only treatment 
which could be advised to them was physical and 
occupational therapy shows how restricted our 
knowledge about this disease and its treatment is. 
More case series of this disease needs to be reported 
so that more avenues of research can be identified.       
CONCLUSION:
Charcot-Marie-Tooth is a debilitating disease that 
causes difficulty in difficulty in walking, foot drop, 
muscle wasting and weakness, along with sensory loss 
of distal segments of limbs and reduced or absent 
deep-tendon reflexes. No treatment except for physical 
and occupation therapy can be prescribed for CMT 
patients. Here, we have reported a case series of 3 
siblings diagnosed with CMT disease. Identification of 
this and other such case series helps us to better 
understand this disease and develop treatments for it 
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Figure 1: Pictures of hands and legs of all three patients 
showing classic signs suggestive of 
Charcot-Marie-Tooth Disease. A, B) Pictures of hands 
and legs of Patient 1 shows advance stages of muscle 
contracture and wasting. C, D) Pictures of hands and 
legs of Patient 2 also show advance stages muscle 
contracture and wasting. E, F) Pictures of hands and 
legs of Patient 3 (the youngest of the 3 affected 
siblings) show beginning of signs of muscle contracture 
and wasting.
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